Market-leading healthcare company with a unique diagnostic and therapeutic concept

The company has been an established and profitable player in the consulting sector for the pharmaceutical and healthcare markets for over four decades, distinguished by its tailored software solutions and specialized consulting services. With in-depth industry expertise, a focus on the DACH region, and involvement in global projects, it helps pharmaceutical and medical technology companies optimize their workflows and processes. Thanks to its ability to boost efficiency and productivity through innovative digital solutions, the company enjoys a respected position in a highly competitive environment.

The company positions itself as a pharmaceutical importer with over a decade of market presence and an extensive customer base throughout Germany. It is characterized by stable supply chains and offers a diverse pharmaceutical portfolio. A significant competitive advantage stems from its first-class service offerings and existing approvals, which have enabled the company to successfully position itself in the B2B sector—primarily with wholesale partners and pharmacies—as well as in contract manufacturing, including refrigerated products. In addition, framework and discount agreements with key players in the healthcare sector strengthen the company’s growing market position.

An established pharmaceutical company is opening up to new investors after existing minority shareholders expressed a desire to sell their shares. The company, which has been in business for over 40 years, is the European market leader in a specialized niche market with a near-monopoly position and wields impressive pricing power across large portions of its extensive product portfolio. The company develops, manufactures, and distributes approximately 700 high-quality products under GMP certifications from Swissmedic and the FDA (U.S.). In addition, the company offers services in the areas of documentation and contract manufacturing. A key USP lies in its unique international supplier network and first-class regulatory documentation, which is highly regarded worldwide. With a workforce of about 40 employees in Switzerland and another 10 abroad, the company exports its products to more than 50 countries. The domestic market, accounting for about 50% of sales, also contributes substantially to the company’s success. Thanks to strategic investments and measures already implemented, the company is on a growth trajectory and plans to double its revenue within the next five years—with a target EBITDA margin of at least 20%. The company plans to distribute 40% of net income before taxes as dividends in the future, increasing this to 50% later on. Initially, the return on invested capital is approximately 4% and is expected to rise to about 8% over the next five years in line with anticipated growth. A total of approximately 200 shares can be purchased at a price of CHF 6,000 each, which corresponds to about 16% of the share capital. Partial lots of 20 shares or more are also available for sale. This investment provides access to a profitable, established, and internationally active pharmaceutical company with a stable market position and attractive long-term return potential.

A "ready to scale" wellness technology company specializing in cold and contrast therapy is for sale at a purchase price of 200,000 euros . The company holds an EU patent application for an ice bath that generates real ice directly in the tub and is positioned in the rapidly growing market for modern recovery solutions. The company has already achieved successful market validation and generated approximately 138,000 euros in revenue in 2025 through organic growth alone . In Q1 2026, it has already generated approximately 106,000 euros in revenue . The sales structure includes a fully functional online store, established supply chains, and initial distribution partnerships in the B2B and B2C sectors. A key investment highlight: The purchase price of 200,000 euros includes an extensive inventory with a retail value of approximately 230,000 euros . This inventory can be used immediately to generate revenue without further reinvestment . In addition, the company is eligible for BAFA-INVEST funding (25% grant) for investors. The sale is taking place for health reasons. To ensure the company’s scaling up to market leadership, the current managing director will be available long-term for a transition phase as well as for ongoing strategic consulting .

The company is positioning itself in Germany’s dynamic digital health sector and offers an innovative platform that uses data-driven matching to provide services such as medical history reviews, treatment recommendations, and referrals to users in the fields of conventional and complementary medicine. With a focused approach on self-paying patients, the company has validated its product-market fit (PMF) by already onboarding 100 providers. Through its freemium business model and focus on scalable micro-markets, the company clearly distinguishes itself from traditional appointment portals, particularly through the integration of medical logic into its offering. Given its goal of tapping into a growing market worth 38 billion euros with an annual growth rate of 16.8%, the company represents an attractive opportunity for investors to position themselves in a promising and technology-driven sector.